Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Revenue	32.33	11.76	1.94	-	-	Upgrade
Revenue Growth (YoY)	174.98%	505.77%	-	-	-	Upgrade
Cost of Revenue	22.85	19.13	12.49	68.2	35.37	Upgrade
Gross Profit	9.48	-7.37	-10.55	-68.2	-35.37	Upgrade
Selling, General & Admin	56.65	49.94	37.53	18.87	5.26	Upgrade
Research & Development	181.5	165.82	117.61	-	-	Upgrade
Operating Expenses	238.14	215.76	155.14	18.87	5.26	Upgrade
Operating Income	-228.66	-223.12	-165.69	-87.07	-40.63	Upgrade
Interest & Investment Income	28.76	23.17	6.87	0.14	0.16	Upgrade
Other Non Operating Income (Expenses)	1.54	0.17	1.49	-33.39	-5.24	Upgrade
Pretax Income	-198.36	-199.79	-157.33	-120.31	-45.7	Upgrade
Income Tax Expense	0.35	0.28	0.05	-	-	Upgrade
Net Income	-198.71	-200.07	-157.39	-120.31	-45.7	Upgrade
Net Income to Common	-198.71	-200.07	-157.39	-120.31	-45.7	Upgrade
Shares Outstanding (Basic)	85	64	54	27	2	Upgrade
Shares Outstanding (Diluted)	85	64	54	27	2	Upgrade
Shares Change (YoY)	32.02%	18.79%	101.04%	1094.26%	76.18%	Upgrade
EPS (Basic)	-2.35	-3.12	-2.91	-4.48	-20.31	Upgrade
EPS (Diluted)	-2.35	-3.12	-2.91	-4.48	-20.31	Upgrade
Free Cash Flow	-161.43	-158.83	-135.56	-82.24	-38.69	Upgrade
Free Cash Flow Per Share	-1.91	-2.48	-2.51	-3.06	-17.19	Upgrade
Gross Margin	29.33%	-62.66%	-	-	-	Upgrade
Operating Margin	-707.23%	-1897.64%	-8536.17%	-	-	Upgrade
Profit Margin	-614.59%	-1701.55%	-8108.55%	-	-	Upgrade
Free Cash Flow Margin	-499.28%	-1350.84%	-6984.23%	-	-	Upgrade
EBITDA	-221.91	-217.67	-162.88	-85.53	-39.3	Upgrade
D&A For EBITDA	6.75	5.46	2.8	1.54	1.33	Upgrade
EBIT	-228.66	-223.12	-165.69	-87.07	-40.63	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q